The intended audience for the activity is ophthalmologists and other health care professionals involved in the treatment of patients with ocular disorders.
Upon completion of this activity, attendees should be better able to:
Examine preferred techniques and technology in cataract surgery such as intraoperative aberrometry, IOL exchange and power calculations, the use of femtosecond laser, and capsulotomy devices.
Review complex cases and complications management in cataract surgery.
Summarize practice pearls in premium and toric IOL implantation and state-of-the-science cataract surgical techniques and the latest evidence-based recommendations.
Analyze the safety and efficacy of new or refined strategies for managing corneal health, including: evidence-based dosing regimens for anti-infective and anti-inflammatory drugs in cataract and refractive surgery and the rationale behind them, the latest advances in treating corneal disease, and the latest evidence on the treatment of dry eye and ocular allergy.
Discuss challenging and controversial cases pertaining to femtosecond cataract surgery and refractive IOLs.
Evaluate state-of-the-science astigmatism management as it relates to preoperative measurements, corneal conditions, use of toric IOLs, femtosecond nomograms, and enhancements.
Evaluate new evidence on corneal-based and lens-based refractive surgery, including diagnostic technology, ocular surface optimization, presbyopia, and patient selection.
Assess new evidence and applications in the medical and surgical management of retinal vascular disorders and diseases.
Review the latest techniques and technologies in glaucoma, including minimally invasive glaucoma surgery, trabeculectomy, tube shunts, astigmatic correction, and cataract surgery.
Examine how new practice management services and shared decision-making approaches, integrated into the daily office flow, can better serve patients.
Upon successful completion of this activity, participants should be better able to:
Assess the role of nitric oxide in the regulation of the conventional outflow pathway.
Evaluate the efficacy and safety of new and emerging nitric oxide-based agents for the treatment of patients with glaucoma.
This continuing medical education activity is provided by
OSN New York 2018 is supported, in part, by independent medical education grants from Aerie Pharmaceuticals, Inc.; Alcon Laboratories, Inc.; Allergan, Inc.; Bausch + Lomb; Carl Zeiss Meditec, Inc., Regeneron Pharmaceuticals, Inc.; and Sun Pharmaceutical Industries, Inc.
ACCREDITATION: Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION: Vindico Medical Education designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.
NOTICE: Faculty, topics, program schedule and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance.